Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 8/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504394 | 0.89 | DDX3X (0.41) | KCNH2RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL21623471 | 0.89 | DDX3X (0.41) | KCNH2RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL21623435 | 0.86 | RXRA (0.42) | RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL31504417 | 0.86 | RXRA (0.42) | RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL21623400 | 0.86 | RXRA (0.38) | KCNH2RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL31504429 | 0.86 | RXRA (0.38) | KCNH2RXRAGRIN1GRIN2BMCHR1 | |
| SCHEMBL21617195 | 0.79 | MET (0.44) | TYK2JAK3MCHR1 | |
| SCHEMBL23308001 | 0.76 | JAK2 (0.39) | KCNH2RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL23272832 | 0.75 | TYK2 (0.39) | TYK2JAK3MCHR1 | |
| SCHEMBL31504427 | 0.75 | TYK2 (0.39) | TYK2JAK3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820850-B1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-09-23 | — | — | US | disclosed |
| EP-3820850-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | NSUN3, CBR3, C1R | KCNH2 1548/4885RXRA 1617/4885GRIN1 3308/4885 |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | NSUN3, CBR3, C1R | KCNH2 1548/4885RXRA 1617/4885GRIN1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.